核结合因子-急性髓细胞白血病的治疗现状

摘要

核心结合因子-急性髓细胞白血病(CBF-AML)包括伴有t(8;21)(q22;q22) AML与伴有inv(16)(p13q22)/t(16;16)(p13;q22) AML 2种类型.CBF-AML患者对大剂量化疗敏感,预后良好.但是,近年来研究发现CBF-AML的预后具有异质性,对其进行危险度分层治疗为目前国际趋势.大剂量阿糖胞苷治疗仍为CBF-AML的首选治疗方案,异基因造血于细胞移植(allo-HSCT)为治疗高危、复发患者的重要手段,靶向药物的出现亦为CBF-AML的治疗提供了新希望.为了指导临床CBF-AML的治疗,笔者拟就CBF-AML的临床治疗研究进展进行介绍.%There are two typies of core-binding factor-acute myeloid leukemia (CBF-AML),including t(8;21)(q22;q22) AML and inv(16)(p13q22)/t(16;16)(p13;q22) AML.Patients with CBF-AML are sensitive to high-dose chemotherapy and have good prognosises.However,recent studies have showed that outcome of CBF-AML is heterogeneous.Risk stratification therapy has become the mainstream at present.High-dose cytarabine is still the first choice for CBF-AML treatment.Moreover,allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important strategy for high-risk relapse patients.Emergence of targeted drugs also provides new hope for treatment of CBF-AML.This article focuses on the advances in clinical research to provide guide for treatment of CBF-AML.